Poxel SA

Poxel SA est membre de Lyonbiopôle

General information

259/261 avenue Jean Jaurès

69007 Lyon

Incorporated in: 2009/03/11

Number of employees: 23

More information


Main activity

Created in 2009 as a spin out of Merck Serono, Poxel is a dynamic biopharmaceutical company that uses its extensive expertise in developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). In its mid-to-late stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities. Imeglimin, Poxel’s first-in-class lead drug candidate targeting mitochondrial dysfunction. Together, with its partner Sumitomo Dainippon Pharma, Poxel is conducting the Phase 3 TIMES program of Imeglimin for the treatment of type 2 diabetes in Japan. Poxel also established a partnership with Roivant Sciences for Imeglimin’s development and commercialization in countries outside of the partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, Poxel's first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, entered a Phase 2a proof-of-concept program for the treatment of NASH in early April 2019 with results expected in the second quarter of 2020. PXL065, Poxel’s mitochondrial pyruvate carrier (MPC) inhibitor, entered a Phase 1b multiple ascending dose trial in September 2019 and this Phase 1 NASH program is expected to be completed in the fourth quarter of 2019.


Looking for funding: Yes

Private funding obtained: €34m from Edmond de Rothschild Investment Partners,Bpi France and Omnes Capital (ex-Credit Agricole Private Equity)

Public funding obtained: Sept. 2009: €215,000 grant from FEDER and €250,000 grant from Le Grand Lyon for  NATHEB project. Oct. 2011: €1.45m from OSEO

Stock exchange listing: Listed on Euronext on February 6, 2015: €26;8 M raised

Products / Services / Technologies
Partnership opportunities / Licensing

Strategic area of application
Human Medicine

Application market
Metabolic Diseases

Therapeutics, Pharma or Biotech